What is the reported incidence of reflux on semaglutide in ESSENCE?

What I am working with: reflux · semaglutide · ESSENCE.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

Which parts of this are informative and which are decoration?

The short version: dose-related, escalation-concentrated, mostly attenuating except for constipation, and manageable by titration pace more than anything else.

Anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.

Local reaction versus infection

The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.

Symptoms appearing late at a stable dose deserve a differential diagnosis rather than an assumption.

Everything except constipation attenuates. Plan differently for that one.

Diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.

Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.

Concretely, symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.

Research-use compounds are not approved for human use.

Smaller meals, less fat, fluids between rather than with. In that order.

Answer first: the gastrointestinal effects in this class share one mechanism — slowed gastric emptying plus central signalling — and present as nausea, fullness, reflux, constipation or diarrhoea depending on the person.

Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.

Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.

The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.

Slow the titration first. It is the intervention with the best evidence and the lowest cost.

Answering this needs the titration history, because going faster than the schedule is the single largest modifiable factor.

Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.

Most people who report these effects continue. The discontinuation rate is low.

Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.

Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.

Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.

Nothing here is medical advice.

New symptoms at a stable dose after months need a different explanation.

edited 17 Feb 2025 by Dr_Ilse_Vandenberg — added a caveat about sampling